For more details on our visitation guidelines, please speak with a nurse
or patient information representative. Read more ›
Kendall Sawa has been named chief operating officer for Providence Portland Medical Center. Sawa currently serves as the chief executive for Providence Seaside Hospital and North Coast Service Area. He will begin his new role Nov. 5.
Krista Farnham has been named chief executive for Providence Portland Medical Center and will lead Providence Oregon’s eastern region.
In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.
Providence’s commitment to patient safety is a high priority among caregivers and that has been recognized by the Oregon Patient Safety Commission. All eight Providence hospitals in Oregon and Providence’s Center for Medically Fragile Children, a residential care facility for young people, were recognized by the commission for meeting an assortment of patient safety targets.
More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing access to treatment and improving care to freeing trapped data and unleashing new breakthroughs.
An increased focus on compassionate care work means the long-term program director of Providence Portland Medical Center’s internal medicine residency program will step aside, bringing new, but well-known, leadership to the group.
Providence Oral, Head and Neck Cancer Clinics now serve patients at two locations: Providence Portland Medical Center and a newly opened clinic at Providence St. Vincent Medical Center.
Providence Cancer Center researchers have initiated several important clinical trials to investigate the effectiveness of promising new immunotherapies to treat patients with head and neck cancers.
Researchers at Providence Cancer Center received a $75,000 grant to study biomarkers that may help predict responses to immuntherapy and assist oncologists in making treatment-related decisions for patients with head and neck cancers.